Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort
(2012) In British Journal of Cancer 106(11). p.1866-1874- Abstract
- BACKGROUND: Established risk factors for pancreatic cancer include smoking, long-standing diabetes, high body fatness, and chronic pancreatitis, all of which can be characterised by aspects of inflammatory processes. However, prospective studies investigating the relation between inflammatory markers and pancreatic cancer risk are scarce. METHODS: We conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition, measuring prediagnostic blood levels of C-reactive protein (CRP), interleukin-6 (IL-6), and soluble receptors of tumour necrosis factor-a (sTNF-R1, R2) in 455 pancreatic cancer cases and 455 matched controls. Odds ratios (ORs) were estimated using conditional logistic regression... (More)
- BACKGROUND: Established risk factors for pancreatic cancer include smoking, long-standing diabetes, high body fatness, and chronic pancreatitis, all of which can be characterised by aspects of inflammatory processes. However, prospective studies investigating the relation between inflammatory markers and pancreatic cancer risk are scarce. METHODS: We conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition, measuring prediagnostic blood levels of C-reactive protein (CRP), interleukin-6 (IL-6), and soluble receptors of tumour necrosis factor-a (sTNF-R1, R2) in 455 pancreatic cancer cases and 455 matched controls. Odds ratios (ORs) were estimated using conditional logistic regression models. RESULTS: None of the inflammatory markers were significantly associated with risk of pancreatic cancer overall, although a borderline significant association was observed for higher circulating sTNF-R2 (crude OR = 1.52 (95% confidence interval (CI) 0.97-2.39), highest vs lowest quartile). In women, however, higher sTNF-R1 levels were significantly associated with risk of pancreatic cancer (crude OR = 1.97 (95% CI 1.02-3.79)). For sTNF-R2, risk associations seemed to be stronger for diabetic individuals and those with a higher BMI. CONCLUSION: Prospectively, CRP and IL-6 do not seem to have a role in our study with respect to risk of pancreatic cancer, whereas sTNF-R1 seemed to be a risk factor in women and sTNF-R2 might be a mediator in the risk relationship between overweight and diabetes with pancreatic cancer. Further large prospective studies are needed to clarify the role of proinflammatory proteins and cytokines in the pathogenesis of exocrine pancreatic cancer. British Journal of Cancer (2012) 106, 1866-1874. doi:10.1038/bjc.2012.172 www.bjcancer.com Published online 26 April 2012 (C) 2012 Cancer Research UK (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2802885
- author
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- inflammation, pancreatic cancer, EPIC, CRP, IL-6, TNF receptor
- in
- British Journal of Cancer
- volume
- 106
- issue
- 11
- pages
- 1866 - 1874
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000304353500023
- scopus:84861442915
- pmid:22617158
- ISSN
- 1532-1827
- DOI
- 10.1038/bjc.2012.172
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)
- id
- 9a4135d6-6cbb-4dd3-b008-7c973b505fb3 (old id 2802885)
- date added to LUP
- 2016-04-01 10:16:47
- date last changed
- 2022-05-17 21:31:38
@article{9a4135d6-6cbb-4dd3-b008-7c973b505fb3,
abstract = {{BACKGROUND: Established risk factors for pancreatic cancer include smoking, long-standing diabetes, high body fatness, and chronic pancreatitis, all of which can be characterised by aspects of inflammatory processes. However, prospective studies investigating the relation between inflammatory markers and pancreatic cancer risk are scarce. METHODS: We conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition, measuring prediagnostic blood levels of C-reactive protein (CRP), interleukin-6 (IL-6), and soluble receptors of tumour necrosis factor-a (sTNF-R1, R2) in 455 pancreatic cancer cases and 455 matched controls. Odds ratios (ORs) were estimated using conditional logistic regression models. RESULTS: None of the inflammatory markers were significantly associated with risk of pancreatic cancer overall, although a borderline significant association was observed for higher circulating sTNF-R2 (crude OR = 1.52 (95% confidence interval (CI) 0.97-2.39), highest vs lowest quartile). In women, however, higher sTNF-R1 levels were significantly associated with risk of pancreatic cancer (crude OR = 1.97 (95% CI 1.02-3.79)). For sTNF-R2, risk associations seemed to be stronger for diabetic individuals and those with a higher BMI. CONCLUSION: Prospectively, CRP and IL-6 do not seem to have a role in our study with respect to risk of pancreatic cancer, whereas sTNF-R1 seemed to be a risk factor in women and sTNF-R2 might be a mediator in the risk relationship between overweight and diabetes with pancreatic cancer. Further large prospective studies are needed to clarify the role of proinflammatory proteins and cytokines in the pathogenesis of exocrine pancreatic cancer. British Journal of Cancer (2012) 106, 1866-1874. doi:10.1038/bjc.2012.172 www.bjcancer.com Published online 26 April 2012 (C) 2012 Cancer Research UK}},
author = {{Grote, V. A. and Kaaks, R. and Nieters, A. and Tjonneland, A. and Halkjaer, J. and Overvad, K. and Nielsen, M. R. Skjelbo and Boutron-Ruault, M. C. and Clavel-Chapelon, F. and Racine, A. and Teucher, B. and Becker, S. and Pischon, T. and Boeing, H. and Trichopoulou, A. and Cassapa, C. and Stratigakou, V. and Palli, D. and Krogh, V. and Tumino, R. and Vineis, P. and Panico, S. and Rodriguez, L. and Duell, E. J. and Sanchez, M-J and Dorronsoro, M. and Navarro, C. and Gurrea, A. B. and Siersema, P. D. and Peeters, P. H. M. and Ye, W. and Sund, M. and Lindkvist, B. and Johansen, Dorthe and Khaw, K-T and Wareham, N. and Allen, N. E. and Travis, R. C. and Fedirko, V. and Jenab, M. and Michaud, D. S. and Chuang, S-C and Romaguera, D. and Bueno-de-Mesquita, H. B. and Rohrmann, S.}},
issn = {{1532-1827}},
keywords = {{inflammation; pancreatic cancer; EPIC; CRP; IL-6; TNF receptor}},
language = {{eng}},
number = {{11}},
pages = {{1866--1874}},
publisher = {{Nature Publishing Group}},
series = {{British Journal of Cancer}},
title = {{Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort}},
url = {{http://dx.doi.org/10.1038/bjc.2012.172}},
doi = {{10.1038/bjc.2012.172}},
volume = {{106}},
year = {{2012}},
}